A polymorphism in the coding sequence of WT1 is an independent prognostic marker in 1,101 patients with lobular breast cancer.

Authors:
  • MHM. Heuser
    M. Heuser
  • FDF. Damm
    F. Damm
  • PSP. Schuermann
    P. Schuermann
  • MZM. Zucknick
    M. Zucknick
  • MSM. Shah
    M. Shah
  • PHP. Harrington
    P. Harrington
  • PPP. Pharoah
    P. Pharoah
  • MSM. Schmidt
    M. Schmidt
  • RHR. van Hien
    R. van Hien
  • RTR. A. Tollenaar
    R. A. Tollenaar
  • HNH. Nevanlinna
    H. Nevanlinna

Abstract
10558 Background: We have recently shown that a single nucleotide polymorphism (SNP) in WT1 exon 7 (rs16754) is associated with prognosis in patients with acute myeloid leukemia. To test whether SNP rs16754 is also associated with outcome in other cancers, we investigated the role of this SNP as a candidate polymorphism for breast cancer (BC) survival in a large cohort of BC patients in the context of other prognostic markers. Methods: WT1 SNP rs16754 was genotyped using a TaqMan genotyping assay and genomic DNA from 8,337 BC patients from four European studies of the Breast Cancer Association Consortium (BCAC). The effect of rs16754 genotypes on overall survival was assessed in univariate and multivariate analysis adjusting for known prognostic markers. Results: The minor allele of SNP rs16754 was found heterozygous in 25.2% and homozygous in 2.8% of all studied BC patients. Patient characteristics and pathologic findings were similarly distributed between patients homozygous for the major allele compared to patients heterozygous or homozygous for the minor allele. Overall survival (OS) of patients with lobular BC and at least one minor allele of WT1 SNP rs16754 was significantly shorter compared to patients with lobular BC who were homozygous for the major allele (HR 1.54, 95% CI 1.15 to 2.06, P=.004; 10-year OS 71% vs 81%. Importantly, breast cancer specific survival (BCSS) was significantly shorter in lobular BC patients with at least one minor allele of SNP rs16754 compared to patients who were homozygous for the major allele (HR, 1.55, 95% CI 1.13 to 2.14 , P=.007). In patients with invasive lobular BC (n=1,101), SNP rs16754 status was an independent predictor of OS and BCSS in multivariate analysis (HR 1.44, 95% CI 1.06-1.94, P=.018 and HR 1.49, 95% CI 1.07-2.07, P=.018, respectively) adjusting for nodal status, ER, PR, HER2 status, tumor grade and age. The unfavorable effect of SNP rs16754 became most apparent five years after diagnosis, and was strongest in hormone-receptor positive and in younger patients with lobular BC. Conclusions: WT1 SNP rs16754 may therefore become useful as an independent poor-risk marker in lobular breast cancer patients that might improve risk and treatment stratification.